BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Esreboxetine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Esreboxetine\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07398417-10867@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Esreboxetine: Phase 3 readout est. (NCT07398417)
DESCRIPTION:Esreboxetine\, phase 3\, Fibromyalgia.\nStudy: Fibromyalgia Res
 ponse With Esreboxetine Evaluated Using a Randomized Withdrawal Research D
 esign\nEstimated primary completion: March 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/esreboxetine#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07398417
URL:https://assetmemo.bio/drug/esreboxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07637162-10867@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Esreboxetine: Phase 3 readout est. (NCT07637162)
DESCRIPTION:Esreboxetine\, phase 3\, Fibromyalgia.\nStudy: Open-Label Safet
 y Study of AXS-14 in Subjects With Fibromyalgia\nEstimated primary complet
 ion: May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/esrebo
 xetine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07637162
URL:https://assetmemo.bio/drug/esreboxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
